Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLNO | SOLENO THERAPEUTICS INC | $1.74B | $33.76 | $92.50 | 174.03% | Strong Buy | 4 | 101.94% | 324.84% | 119.61% | 95.49% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $41.57B | $313.41 | $473.06 | 50.94% | Strong Buy | 18 | 33.97% | 83.15% | 348.08% | 55.31% | |||
| ADMA | ADMA BIOLOGICS INC | $3.61B | $15.15 | N/A | N/A | N/A | N/A | 23.04% | 36.37% | 109.42% | 83.67% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $585.94M | $9.98 | $24.00 | 140.48% | Strong Buy | 2 | 42.07% | 24.36% | 125.56% | 68.20% | |||
| CORT | CORCEPT THERAPEUTICS INC | $3.42B | $32.15 | $85.00 | 164.39% | Buy | 3 | 27.12% | 64.76% | 102.67% | 79.50% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $382.78M | $4.78 | $13.00 | 171.97% | Strong Buy | 1 | 21.12% | 45.24% | 67.24% | 48.36% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.51B | $63.66 | $78.56 | 23.40% | Buy | 9 | 16.31% | 60.08% | 2,350.14% | 45.43% | |||
| XOMA | XOMA ROYALTY CORP | $326.67M | $26.38 | $67.00 | 153.98% | Strong Buy | 4 | 41.63% | 37.69% | N/A | N/A | |||
| ABEO | ABEONA THERAPEUTICS INC | $257.95M | $4.76 | $20.00 | 320.17% | Buy | 1 | 817.16% | 17.16% | 81.99% | 60.75% | |||
| KRYS | KRYSTAL BIOTECH INC | $7.23B | $247.26 | $326.25 | 31.95% | Strong Buy | 8 | 35.31% | 28.36% | 62.02% | 56.71% | |||
| RPRX | ROYALTY PHARMA PLC | $26.33B | $45.65 | $47.75 | 4.60% | Strong Buy | 4 | 15.44% | 50.65% | 42.64% | 21.11% | |||
| VCEL | VERICEL CORP | $1.65B | $32.54 | $54.50 | 67.51% | Strong Buy | 2 | 17.77% | 56.51% | 22.34% | 16.23% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.25B | $58.51 | $86.73 | 48.24% | Strong Buy | 15 | 12.60% | 56.61% | 28.65% | 22.97% | |||
| APLS | APELLIS PHARMACEUTICALS INC | $2.42B | $18.94 | $32.69 | 72.59% | Buy | 16 | 6.71% | 63.56% | 57.54% | 19.81% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.60B | $27.61 | $42.86 | 55.22% | Buy | 7 | 14.79% | 22.30% | 21.79% | 14.91% | |||
| TECH | BIO-TECHNE CORP | $7.96B | $50.85 | $73.71 | 44.96% | Strong Buy | 7 | 6.01% | 69.71% | 21.86% | 17.43% | |||
| MNKD | MANNKIND CORP | $853.44M | $2.77 | $7.10 | 156.32% | Buy | 5 | 17.83% | 140.36% | -158.09% | 10.18% | |||
| EXEL | EXELIXIS INC | $10.71B | $41.24 | $44.09 | 6.91% | Buy | 11 | 12.76% | 18.63% | 64.86% | 49.28% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.84B | $23.23 | $35.00 | 50.67% | Strong Buy | 1 | 8.59% | 6.96% | 60.44% | 52.24% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $4.05B | $202.91 | $245.00 | 20.74% | Strong Buy | 7 | 10.49% | 18.52% | 22.50% | 14.66% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $78.84B | $745.77 | $830.78 | 11.40% | Buy | 18 | 10.02% | 13.03% | 23.23% | 17.90% | |||
| VCYT | VERACYTE INC | $2.55B | $32.13 | $45.17 | 40.58% | Buy | 6 | 12.30% | 24.92% | 12.54% | 11.68% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $119.23B | $469.34 | $544.55 | 16.02% | Strong Buy | 20 | 10.64% | 16.80% | 39.80% | 28.97% | |||
| CRMD | CORMEDIX INC | $509.88M | $6.45 | $13.50 | 109.30% | Strong Buy | 4 | 15.59% | 0.16% | 37.60% | 18.45% | |||
| INCY | INCYTE CORP | $18.42B | $92.54 | $109.71 | 18.56% | Buy | 14 | 8.44% | 13.91% | 15.10% | 11.21% | |||
| UTHR | UNITED THERAPEUTICS CORP | $23.50B | $536.12 | $581.13 | 8.39% | Buy | 8 | 9.98% | 6.98% | 26.79% | 24.13% | |||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $227.59M | $2.83 | $12.00 | 324.03% | Buy | 1 | 17.29% | 1.00% | 12.28% | 7.90% | |||
| MDXG | MIMEDX GROUP INC | $650.72M | $4.38 | $9.50 | 116.89% | Strong Buy | 4 | 1.96% | 0.61% | 21.26% | 15.92% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.